- Exchange: NYSE MKT LLC
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Protalix BioTherapeutics Inc
+ Add to WatchlistPLX:US
5.2000 USD 0.0400 0.78%As of 20:04:07 ET on 05/20/2013.
Snapshot for Protalix BioTherapeutics Inc (PLX)
| Open: | 5.1600 | Day's Range: | 5.0700 - 5.2600 | Volume: | 42,630 |
|---|---|---|---|---|---|
| Previous Close: | 5.2000 | 52wk Range: | 4.7100 - 6.8000 | 1-Yr Rtn: | -18.95% |
Key Statistics for PLX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.1200 |
| Est. EPS (USD) (12/2013) | -0.1270 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 488.09 |
| Shares Outstanding (M) | 93.50 |
| 30 Day Average Volume | 160,675 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | 13.8249 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for PLX
Company Profile & Key Executives for PLX
Protalix BioTherapeutics Inc. is a biotechnology company that has developed plant cell culture technology and a bioreactor system.
| David AviezerPresident/CEO | Tzvi PalashChief Operating Officer |
| Yoseph ShaaltielExec VP:Research & Development | Einat Brill AlmonSenior VP:Product Development |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
PLX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page